August 19th, 2009 – Metagenics, Inc. – MetaProteomics, LLC, the biotechnology unit of Metagenics, Inc. announced today that is has acquired a ThalesNano H-Cube instrument. This innovative device utilizes continuous-flow technology to generate in situ hydrogen, a process crucial to phytochemical research for selectively transforming organic compounds in order to study their health-improving properties.
Compared to traditional approaches such as batch flow technology, the H-Cube is faster, less expensive, and usually provides greater yields. The H-Cube is a standalone small bench-top device that produces hydrogen on demand in trace amounts. Hydrogen storage is not required, which results in a much smaller footprint and a more economical use of space. The transformations occur on environmentally friendly, disposable catalyst modeled after larger micro-flow systems.
Brian Carroll, PhD, senior scientist at MetaProteomics said: “We are privileged in joining other world-class research laboratories that are using this innovative technology offered by ThalesNano. This and other flow-techniques enable our natural products scientists to achieve their objectives with less costs and greater sustainability for our environment.”
About Metagenics, Inc.
Metagenics, headquartered in San Clemente, CA, is a global life sciences company focused on reversing chronic illness and improving health. Founded in 1983, the company serves tens of thousands of health care professionals and more than a million patients throughout the world and holds more than 40 proprietary formula patents for use in nutraceuticals, medical foods, and pharmaceuticals. Today, Metagenics continues its leadership role by successfully merging the disciplines of nutritional genomics, functional medicine, and therapeutic lifestyle change programs to find solutions to society’s most pressing health concerns. For more information, please visit http://www.metagenics.com.
About MetaProteomics, LLC
MetaProteomics is focused on discovering and developing proprietary, orally bioavailable, small molecule therapeutics for prevention and treatment of chronic diseases such as type 2 diabetes, cardiometabolic syndrome, vascular diseases, osteoporosis, osteoarthritis, autoimmune inflammatory diseases, and specific cancers. MetaProteomics screens natural molecules with a history of safe use with its ExpresSyn® selective kinase response modulator (SKRM) discovery platform to identify bioactive therapeutics that can be safely used for long-term therapy for chronic disease as drugs or as nutritionals incorporated into therapeutic lifestyle change programs. MetaProteomics rapidly commercializes its proprietary nutritional discoveries as medical foods, nutraceuticals, and OTC drugs while concurrently developing prescription drugs from the most bioactive candidates. MetaProteomics is a subsidiary of Metagenics, Inc.